Education
About Us
Working with TipRanks
Follow Us
Fate Therapeutics (FATE)
NASDAQ:FATE
FATE Stock Chart & Stats
$1.37
-$0.10(-5.71%)
At close: 4:00 PM EST
$1.37
-$0.10(-5.71%)
Day’s Range― - ―
52-Week Range$0.66 - $1.94
Previous CloseN/A
Volume630.90K
Average Volume (3M)1.62M
Market Cap
$174.40M
Enterprise Value$188.68M
Total Cash (Recent Filing)$203.66M
Total Debt (Recent Filing)$77.85M
Price to Earnings (P/E)―
Beta1.85
Next Earnings
May 06, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding116,263,460
10 Day Avg. Volume1,843,559
30 Day Avg. Volume1,616,435
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.56
Price to Sales (P/S)17.56
P/FCF Ratio-1.04
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue28.39
Enterprise Value/Gross Profit-30.16
Enterprise Value/Ebitda-1.35
Forecast
1Y Price Target
$3.83Price Target Upside179.56% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-1.12
Revenue Forecast (FY)$5.85M
Bulls Say, Bears Say
Bulls Say
Early Clinical Activity Across Autoimmune IndicationsEarly clinical signals, including measurable improvement in a treated systemic sclerosis patient across several clinical measures, suggest the therapy may have activity across multiple autoimmune disorders and could broaden its market potential.
Regulatory Fast-track And Pivotal PathA regulatory fast-track designation supports plans for a pivotal trial in systemic lupus erythematosus and lupus-related kidney disease, potentially shortening the pathway to approval if confirmatory data are achieved.
Trial Enrollment ExpansionEnrollment in FT819 trials is expanding across multiple international sites, including additional European centers, which can speed data collection and support more robust clinical readouts.
Bears Say
Investor Risk From Data VariabilityLimited patient numbers make early efficacy and safety signals vulnerable to variability, raising the risk of significant share-price volatility if subsequent results do not confirm initial findings.
Limited Patient DataThe program has treated only a small number of patients, which limits confidence in conclusions about safety and effectiveness until larger datasets are available.
Regulatory Uncertainty From Small CohortsSmall trial cohorts increase regulatory uncertainty because authorities typically expect broader safety and efficacy evidence before granting approval for a novel cell therapy.
Fate Therapeutics News
FATE FAQ
What was Fate Therapeutics’s price range in the past 12 months?
Fate Therapeutics lowest stock price was $0.66 and its highest was $1.94 in the past 12 months.
What is Fate Therapeutics’s market cap?
Fate Therapeutics’s market cap is $174.40M.
When is Fate Therapeutics’s upcoming earnings report date?
Fate Therapeutics’s upcoming earnings report date is May 06, 2026 which is in 63 days.
How were Fate Therapeutics’s earnings last quarter?
Fate Therapeutics released its earnings results on Feb 26, 2026. The company reported -$0.27 earnings per share for the quarter, the consensus estimate of -$0.27 by $0.
Is Fate Therapeutics overvalued?
According to Wall Street analysts Fate Therapeutics’s price is currently Undervalued.
Does Fate Therapeutics pay dividends?
Fate Therapeutics does not currently pay dividends.
What is Fate Therapeutics’s EPS estimate?
Fate Therapeutics’s EPS estimate is -0.28.
How many shares outstanding does Fate Therapeutics have?
Fate Therapeutics has 116,263,460 shares outstanding.
What happened to Fate Therapeutics’s price movement after its last earnings report?
Fate Therapeutics reported an EPS of -$0.27 in its last earnings report, expectations of -$0.27. Following the earnings report the stock price went up 5.405%.
Which hedge fund is a major shareholder of Fate Therapeutics?
Currently, no hedge funds are holding shares in FATE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fate Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.83 (179.56% Upside)
$3.83 (179.56% Upside)
Blogger Sentiment
Bullish
FATE Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 629.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $16.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.9%
Last 30 Days ▼ 8.6%
Last 30 Days ▼ 8.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.92%
12-Months-Change
Fundamentals
Return on Equity
-51.84%
Trailing 12-Months
Asset Growth
-27.63%
Trailing 12-Months
Company Description
Fate Therapeutics
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
FATE Stock 12 Month Forecast
Average Price Target
$3.83
▲(179.56% Upside)
Technical Analysis
Ownership Overview
13.10% Insiders
13.03% Mutual Funds
1.72% Other Institutional Investors
63.05% Public Companies and
Individual Investors